坏死性凋亡相关复合物与肿瘤

国际肿瘤学杂志››2018,Vol. 45››Issue (10): 624-626.doi:10.3760/cma.j.issn.1673-422X.2018.10.010

丁金晔,程忠平

200072 同济大学附属上海市第十人民医院妇产科

收稿日期:2018-04-10出版日期:2018-10-08发布日期:2018-12-21
通讯作者:程忠平 E-mail:mdcheng18@tongji.edu.cn

Complexities in necroptosis and tumor

Ding Jinye, Cheng Zhongping

Department of Gynecology and Obstetrics, Tenth People′s Hospital Affiliated to Tongji University, Shanghai 200072, China

Received:2018-04-10Online:2018-10-08Published:2018-12-21
Contact:Cheng Zhongping E-mail:mdcheng18@tongji.edu.cn

摘要/Abstract

摘要：坏死性凋亡相关复合物是坏死性凋亡信号通路中的关键信号分子。它的形成受到坏死小体和坏死性凋亡小体等一系列因素的调控。研究发现，坏死性凋亡相关复合物与多种肿瘤密切相关，如胰腺导管腺癌、胶质瘤等。深入研究其调控机制有望为肿瘤分子治疗提供新思路。

丁金晔,程忠平. 坏死性凋亡相关复合物与肿瘤[J]. 国际肿瘤学杂志, 2018, 45(10): 624-626.

Ding Jinye, Cheng Zhongping. Complexities in necroptosis and tumor[J]. Journal of International Oncology, 2018, 45(10): 624-626.

［1］ Vanden Berghe T, Linkermann A, JouanLanhouet S, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways［J］. Nat Rev Mol Cell Biol, 2014, 15(2): 134-147. DOI: 10.1038/nrm3737. ［2］ Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincleinduced immune suppression［J］. Nature, 2016, 532(7598): 245-249. DOI: 10.1038/nature17403. ［3］ Lu B, Gong X, Wang ZQ, et al. Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation［J］. Acta Pharmacol Sin, 2017, 38(11): 15431553. DOI: 10.1038/aps.2017.112. ［4］ Seifert L, Miller G. Molecular pathways: the necrosomea target for cancer therapy［J］. Clin Cancer Res, 2017, 23(5): 1132-1136. DOI: 10.1158/1078-0432.CCR-16-0968. ［5］ Liu S, Liu H, Johnston A, et al. MLKL forms disulfide bonddependent amyloidlike polymers to induce necroptosis［J］. Proc Natl Acad Sci U S A, 2017, 114(36): E7450-E7459. DOI: 10.1073/pnas.1707531114. ［6］ Vanden Berghe T, Hassannia B, Vandenabeele P. An outline of necrosome triggers［J］. Cell Mol Life Sci, 2016, 73(1112): 2137-2152. DOI: 10.1007/s00018-016-2189-y. ［7］ Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs［J］. Mol Cell, 2011, 43(3): 432-448. DOI: 10.1016/j.molcel.2011.06.006. ［8］ Dickens LS, Powley IR, Hughes MA, et al. The ′complexities′ of life and death: death receptor signalling platforms［J］. Exp Cell Res, 2012, 318(11): 1269-1277. DOI: 10.1016/j.yexcr.2012.04.005. ［9］ Ali M, Mocarski ES. Proteasome inhibition blocks necroptosis by attenuating death complex aggregation［J］. Cell Death Dis, 2018, 9(3): 346. DOI: 10.1038/s41419-018-0371-x. ［10］ Feoktistova M, Geserick P, Kellert B, et al. cIAPs block Ripoptosome formation, a RIP1/caspase8 containing intracellular cell death complex differentially regulated by cFLIP isoforms［J］. Mol Cell, 2011, 43(3): 449-463. DOI: 10.1016/j.molcel.2011.06.011. ［11］ Hanson B. Necroptosis: a new way of dying?［J］. Cancer Biol Ther, 2016, 17(9): 899-910. DOI: 10.1080/15384047.2016.1210732. ［12］ Su Z, Yang Z, Xie L, et al. Cancer therapy in the necroptosis era［J］. Cell Death Differ, 2016, 23(5): 748756. DOI: 10.1038/cdd.2016.8. ［13］ de Almagro MC, Goncharov T, Newton K, et al. Cellular IAP proteins and LUBAC differentially regulate necrosomeassociated RIP1 ubiquitination［J］. Cell Death Dis, 2015, 6: e1800. DOI: 10.1038/cddis.2015.158. ［14］ Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAPregulated cell deathsignalling platform［J］. J Mol Cell Biol, 2011, 3(6): 324-326. DOI: 10.1093/jmcb/mjr034. ［15］ Schilling R, Geserick P, Leverkus M. Characterization of the ripoptosome and its components: implications for antiinflammatory and cancer therapy［J］. Methods Enzymol, 2014, 545: 83-102. DOI: 10.1016/B978-0-12-801430-1.00004-4. ［16］ McCabe KE, Bacos K, Lu D, et al. Triggering necroptosis in cisplatin and IAP antagonistresistant ovarian carcinoma［J］. Cell Death Dis, 2014, 5: e1496. DOI: 10.1038/cddis.2014.448. ［17］ Shi S, Wang Q, Xu J, et al. Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagymediated apoptosis［J］. Oncotarget, 2015, 6(3): 16401651. DOI: 10.18632/oncotarget.2746. ［18］ Selmi T, Alecci C, dell Aquila M, et al. ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly［J］. BMC Cancer, 2015, 15: 357. DOI: 10.1186/s1288501513885. ［19］ Schroeder A, Warnken U, Roth D, et al. Targeting thioredoxin1 by dimethyl fumarate induces ripoptosomemediated cell death［J］. Sci Rep, 2017, 7: 43168. DOI: 10.1038/srep43168.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.